Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Perceptions of AstraZeneca in Cardiovascular Medicine Research Sample Cardiologist PCP TOTAL France 10 10 20 Italy 10 10 20 UK 10 10 20 TOTAL 30 30 60 Cardiologist Practice Setting Cardiologist Hospital Type One hour In-Depth Interviews (IDIs) with 60 treaters of CV disease across France, Italy and the UK Satisfaction with Current Treatments Atherosclerosis ACS BP Lipids Dissatisfied Satisfied 10 To Slow Atherosclerosis Data shows this can be achieved with high dose statins, however these doses are not often used > Some scepticism about real world practicality "Controlling atherosclerosis is something we'd really like to do, but at the present it's just utopic“ Ita, Card 20 30 40 50 To Prevent Events in ACS Can reduce the risk, but still the biggest risk factor for having a heart attack is already having had one “Drugs are okay, but events still occur - for several different reasons it’s difficult to control“ Fra, PCP 60 70 80 90 100 To Control BP Can get most people to goal but often need combination treatment > Satisfaction would be higher if you could achieve goal with monotherapy To Control Blood Lipids Generally satisfied, good range of drugs available though improved efficacy would be desirable especially in primary prevention “There’s not a magic drug. We get most people controlled on 1,2 or 3 agents with quite a lot of dose adjustment“ UK, Card "I'm satisfied with lipid control because current agents are complete in terms of effects” Ita, Card Satisfaction with ability to control blood lipids and blood pressure is relatively high Base: All respondents (n=60) rated their satisfaction with treatments on a 0 - 100 scale with 100 being fully satisfied Perceived Range of CV Products Perceived Range of CV Products (Mean Rank) AZ Pfizer Sanofi Novartis MSD BMS GSK Bayer Lilly 6 1 5 0 1 5 2 3 3 2 4 AZ, Pfizer and Sanofi were ranked highest for the range of their CV products Base: All respondents (n=60) Respondents ranked top 5 companies, from 1-5, from list of 20 5 Perceived Commitment to and Treatments for CV Disease Overall Importance in Treating CV Disease (Mean Rank) AZ Sanofi Pfizer Novartis “AstraZeneca has a long term commitment to CV – they’ve always been present with various molecules” Fra, Card MSD Lilly BMS Bayer GSK 60 1 5 2 5 3 3 4 2 5 AZ was ranked highest because of their diverse products, their research activity and support of CME Sanofi was second because of their products and the level of support (education, information, materials) they provide Pfizer was third because of their products and their support of CME AZ was ranked highest for its perceived commitment to physicians in treating CV disease, followed by Sanofi, Pfizer and Novartis Base: All respondents (n=60) Respondents ranked top 5 companies, from 1-5, from list of 20 PCPs – Spontaneous Mentions of Franchises (Across all Therapy Areas) Lipid lowering Hypertension/CV Respiratory Lipid lowering Respiratory Gastroenterology Hypertension Diabetology Osteoporosis Many respondents stated that many companies now offer a range of products and are no longer differentiated Rationale for mentioning an individual company was typically current provision of good product(s) rather than service provision etc. AZ mentions centred strongly around lipid lowering with no mentions of other CV products Lipid lowering & Hypertension AZ was mentioned by PCPs most frequently for (lipid lowering> respiratory> gastroenterology franchises) Cardiologists – Spontaneous Mentions of CV Franchises Relatively small number of companies were seen as having a franchise in cardiology Hypertension/OAP Lipid lowering Lipid lowering Hypertension OAP Lipid lowering & Hypertension Hypertension/ Angina Current provision of good product(s) was the main reason for a company to be suggested “The only thing that matters to me is the drug; they all have a betablocker, an ACE inhibitor and a Ca antagonist, no one is better than the others" Ita, PCP Sanofi was most mentioned and was strongly associated with OAP AZ mentions were again centred strongly around lipid lowering with one mention of OAPs Sanofi was most commonly mentioned as having a CV franchise, Pfizer and AZ were seen as leading in lipid lowering CV Franchise Preference Franchise Rankings (Mean Rank) Least willing 1.0 to lose 6.0 2.0 5.0 3.0 4.0 4.0 3.0 5.0 2.0 Most willing 6.0 to lose 1.0 AZ Sanofi Pfizer Novartis MSD Lilly AZ was the CV franchise respondents said they would be least willing to lose because of products, support and innovation Base: All respondents (n=60) Respondents ranked franchises from 6 (would be most willing to lose) to 1 (would be least…) 1478101 10/11